Adrian Rawcliffe, Adaptimmune CEO

#ES­MO22: Adap­ti­m­mune touts new PhI da­ta for its cell ther­a­py treat­ment

As the cell ther­a­py biotech Adap­ti­m­mune has been ea­ger to present da­ta to progress with the FDA, the com­pa­ny hopes that its lat­est show­ing at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.